These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 9200560)

  • 1. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
    Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
    Gillberg PG; Sundquist S; Nilvebrant L
    Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.
    Nilvebrant L; Gillberg PG; Sparf B
    Pharmacol Toxicol; 1997 Oct; 81(4):169-72. PubMed ID: 9353847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological effects of tolterodine on human isolated urinary bladder.
    Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
    Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.
    Nilvebrant L
    Pharmacol Toxicol; 2002 May; 90(5):260-7. PubMed ID: 12076307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse.
    Wüst M; Averbeck B; Reif S; Bräter M; Ravens U
    Eur J Pharmacol; 2002 Nov; 454(1):59-69. PubMed ID: 12409006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.
    Nelson CP; Gupta P; Napier CM; Nahorski SR; Challiss RA
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1255-65. PubMed ID: 15140916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle.
    Yono M; Yoshida M; Takahashi W; Inadome A; Ueda S
    BJU Int; 2000 Oct; 86(6):719-25. PubMed ID: 11069384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
    Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
    Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
    Kobayashi S; Ikeda K; Miyata K
    Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
    Moro C; Uchiyama J; Chess-Williams R
    Urology; 2011 Dec; 78(6):1442.e9-15. PubMed ID: 22001099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers.
    Chapple CR; Nilvebrant L
    Drugs R D; 2002; 3(2):75-81. PubMed ID: 12001821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
    Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
    Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R
    BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
    Chancellor MB; Appell RA; Sathyan G; Gupta SK
    Clin Ther; 2001 May; 23(5):753-60. PubMed ID: 11394733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs].
    Nagao M; Kaneko S; Hirota T; Isogai M; Shimizu H
    Nihon Yakurigaku Zasshi; 1999 Mar; 113(3):157-66. PubMed ID: 10347840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.